Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice

@article{Nakata2017DopamineSP,
  title={Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice},
  author={Yusuke Nakata and Nobuhisa Kanahara and Masaomi Iyo},
  journal={Journal of Psychopharmacology},
  year={2017},
  volume={31},
  pages={1511 - 1518}
}
Dopamine supersensitivity psychosis (DSP) is observed in patients with schizophrenia under antipsychotic treatment, and it is characterized by rebound psychosis, an uncontrollable psychotic episode following a stable state and tardive dyskinesia. DSP, first described in patients taking typical antipsychotics in the late 1970s, sometimes appears even in patients who are treated with current atypical antipsychotics. It was recently demonstrated that DSP can have a negative impact on the long-term… 

Figures from this paper

Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis
TLDR
The findings suggest that unlike first-episode psychosis, the release of dopamine from presynaptic neurons did not increase in relapse episodes in the patients with dopamine supersensitivity psychosis, indirectly indicates that the development of supersensitivity of post-synapse dopamine D2 receptor is involved in relapse in dopamine supers sensitivity psychosis patients.
Long-Term Treatment With Long-Acting Injectable Antipsychotic in Schizophrenia Patients With and Without Dopamine Supersensitivity Psychosis
TLDR
The results indicated the effectiveness of LAI treatment for at least 3 years for patients with DSP, suggesting that this treatment strategy is unlikely to worsen DSP.
Could Some Patients with Treatment-Resistant Schizophrenia Have Reversible Conditions?
  • F. Mustafa
  • Psychology, Medicine
    Psychotherapy and Psychosomatics
  • 2018
TLDR
The suggestion that clozapine efficacy is mediated via its reversal of DS (induced by exposure to other dopamine antagonists) raises the prospect of a potentially reversible TRS that might respond to other antipsychotic drugs that have better side effect profiles and do not require the same strict monitoring.
Twenty-year effects of antipsychotics in schizophrenia and affective psychotic disorders.
TLDR
Even when the confound by indication for prescribing antipsychotic medication is controlled for, participants with schizophrenia and affective psychosis do better than their medicated cohorts, strongly confirming the importance of exposing the role of aiDSP and antipsychotics drug resistance.
Treatment-Resistant Schizophrenia: Genetic and Neuroimaging Correlates
TLDR
The state of art of pharmacogenetic, pharmacogenomic and neuroimaging studies in TRS is summarized to improve knowledge of their action on the central nervous system, with further implications for the discovery of biomarkers and the development of new treatments.
Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia
TLDR
A higher dose of original antipsychotics and prescription of first-generation antipsychotic may be associated with a higher risk of aripiprazole-related psychotic exacerbation, and the underlying mechanism might be covert dopamine supersensitivity psychosis.
Metabolism of risperidone by CYP2D6 and the presence of drug-induced dopamine supersensitivity psychosis in patients with schizophrenia
TLDR
It is suggested that patients with an impaired functional allele of CYP2D6 may have higher concentrations of risperidone and its active metabolite and that these patients may experience more frequent dopamine supersensitivity psychosis episodes.
Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole
TLDR
Otsuka Pharmaceutical Co., Ltd. successfully developed the first dopamine D2 receptor partial agonist approved for schizophrenia, the antipsychotic aripiprazole (Abilify), which was granted marketing approval in the United States in 2015 as adjunctive therapy in major depressive disorder and for the treatment of schizophrenia.
...
...

References

SHOWING 1-10 OF 83 REFERENCES
Efficacy of clozapine on dopamine supersensitivity psychosis in schizophrenia
TLDR
DSP in schizophrenic patients treated with general antipsychotics disappeared over the subsequent 2.5 years under CLZ treatment, suggesting that the agent ameliorates the dopamine supersensitivity state induced by previous antipsychotic treatment.
A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis
TLDR
The association between abnormal involuntary movements and high levels of psychotic symptoms suggests that dopamine sensitization/supersensitivity may underlie both phenomena, and clinicians may have to consider alternative dosing strategies, novel agents or switching to one of the antipsychotics that have a lower affinity for the D2 receptor.
Supersensitivity Psychosis and Its Response to Asenapine in a Patient with Delusional Disorder
  • R. Rajkumar
  • Psychology, Medicine
    Case reports in psychiatry
  • 2014
TLDR
This paper describes a patient with persistent delusional disorder, jealous type, who developed a supersensitivity psychosis characterized by persecutory delusions, auditory hallucinations, and thought insertion in association with mild tardive dyskinesia, which resolved completely following six weeks of treatment with the second-generation antipsychotic asenapine.
Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
TLDR
Data strongly suggest that the continuous blockade of DRD2 by antipsychotic(s) could eventually fail to control the psychosis in some point during long-term treatment, even if such treatment has successfully provided symptomatic improvement for the first-episode psychosis, or stability for the subsequent chronic stage.
Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
TLDR
It is suggested that patients who receive high dosages of antipsychotic drugs form overt or covert DSP and such state is highly associated with psychotic worsening following ARI treatment.
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
TLDR
Criteria for SP is proposed, which describe psychotic symptoms and co-occurring movement disorders more precisely, and 3 antipsychotic withdrawal syndromes are described, similar to those seen with other CNS drugs, and approaches to treat, potentially prevent, or temporarily manage SP are proposed.
Drug-induced supersensitivity psychosis revisited: characteristics of relapse in treatment-compliant patients
TLDR
Clinicians should exercise caution in prescribing and may have to augment treatment with other agents or switch to low dopamine-affinity antipsychotics.
Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes
TLDR
To achieve optimal maintenance treatment with antipsychotic treatment, and to reduce or withdraw antipsychotics effectively, it is proposed that syndromes associated with discontinuing antippsychotics, such as supersensitivity psychosis, from true relapse are distinguished.
Clozapine for the treatment of schizophrenia
TLDR
It is suggested that clozapine is the treatment of choice for schizophrenic patients who are refractory to treatment, display violent behaviors, or who are at high risk of suicide, but it is also the antipsychotic with the worst side effect profile, the highest risk of complications, and the most difficult to prescribe.
...
...